FinnCap Reiterates “Hold” Rating for Immunodiagnostic Systems Hldgs PLC (IDH)
Immunodiagnostic Systems Hldgs PLC (LON:IDH)‘s stock had its “hold” rating restated by FinnCap in a research note issued on Monday. They currently have a GBX 500 ($8.41) target price on the stock. FinnCap’s price target points to a potential upside of 2.31% from the company’s current price.
Shares of Immunodiagnostic Systems Hldgs PLC (LON:IDH) traded down 6.47% on Monday, hitting GBX 488.69. 41,669 shares of the company’s stock traded hands. Immunodiagnostic Systems Hldgs PLC has a 1-year low of GBX 405.00 and a 1-year high of GBX 593.00. The stock’s 50-day moving average is GBX 528.2 and its 200-day moving average is GBX 529.1.
The company also recently declared a dividend, which is scheduled for Friday, August 22nd. Stockholders of record on Wednesday, July 23rd will be given a dividend of GBX 8.50 ($0.14) per share. This represents a yield of 1.57%. The ex-dividend date of this dividend is Wednesday, July 23rd.
A number of other firms have also recently commented on IDH. Analysts at N+1 Singer reiterated a “hold” rating on shares of Immunodiagnostic Systems Hldgs PLC in a research note on Tuesday, June 24th. They now have a GBX 504 ($8.48) price target on the stock. Analysts at Canaccord Genuity raised their price target on shares of Immunodiagnostic Systems Hldgs PLC from GBX 459 ($7.72) to GBX 492 ($8.28) in a research note on Thursday, June 19th. They now have a “hold” rating on the stock. One investment analyst has rated the stock with a sell rating and five have given a hold rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average target price of GBX 511.67 ($8.61).
Immunodiagnostic Systems Holdings plc (LON:IDH) is engaged in manufacturing and distributing medical diagnostic products.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.